Ake­so shares new da­ta sug­gest­ing it can beat Keytru­da on sur­vival, wins Chi­na ap­proval

Ake­so Bio­phar­ma won first-line ap­proval in Chi­na for its lung can­cer drug ivonescimab, a new im­munother­a­py that it be­lieves will top Mer­ck’s megablock­buster PD-1 drug …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER